Baxter presents phase III data for immune deficiency drug HyQ

Baxter has published new interim clinical data evaluating the potential benefits of its primary immune deficiency treatment HyQ.

The company has showcased preliminary findings relating to a limited number of patients enrolled in the ongoing study at the annual European Society for Immunodeficiencies meeting, in order to evaluate its tolerability, bioavailability and infusion volumes.

It was illustrated that immune globulin infusion using subcutaneous administration was successful in the majority of patients, while the treatment was also shown to be well-tolerated, with only mild side effects.

The overall aim of the study will be to demonstrate the drug's efficacy in preventing acute serious bacterial infections.

Dr Hartmut Ehrlich, vice-president of global research and development and medical affairs for Baxter BioScience, said: "The interim results for HyQ are encouraging as we work to bring this therapeutic option to patients."

In August 2010, the company agreed a licensing deal with pharmaceutical firm Kamada to license Glassia, a new treatment for alpha-1 antitrypsin deficiency.